United Kingdom-based pharmaceutical giant AstraZeneca has announced it will cap out-of-pocket costs for its inhalers across the United States at $35 for eligible patients.
The big pharma company announced on March 18 that the cap will start from June 1 onward and apply to its entire range of inhaler products for asthma and chronic obstructive pulmonary disease, including Symbicort, Breztri Aerosphere, and Airsupra inhalers.
